Kardigan appoints Google finance executive Kristin Reinke to Board of Directors. September 30, 2026 Kristin Reinke Kardigan Inc. has appointed longtime Google finance executive Kristin Reinke to its Board of Directors, where she will serve as Chair of the Audit Committee as the precision cardiovascular company advances its late-stage pipeline and continues its evolution as a public company. Reinke's appointment is effective Sept. 29. Doug Giordano, a founding member of Kardigan's board, is stepping down on the same date. Reinke is currently Vice President of Finance at Google, where she leads efforts to apply artificial intelligence to modernize and scale the company's finance organization. She has been a member of Google's finance leadership team since 2005, with responsibilities over the years spanning global financial planning and analysis, capital allocation and controllership. Her appointment adds experience in financial governance and technology-enabled operations to Kardigan's board as the Nasdaq-listed biotechnology company works to advance its cardiovascular drug pipeline toward potential commercialization. "Kristin's proven track record leading AI-driven transformation at global scale will be a great asset to help us achieve our mission of changing the future of cardiovascular care," said Tassos Gianakakos, Co-Founder, Chief Executive Officer and Chair of the Board of Kardigan. Kardigan also expects Reinke's technology background to support its integration of Prolaio's data and analytics platform into the company's product development operations. The company is developing an integrated approach that combines cardiovascular biology, real-world patient data and advanced analytics to inform drug discovery and clinical development. Its pipeline focuses on cardiovascular diseases for which no approved treatments currently exist. "Her experience turning technology into an operational advantage will be invaluable as we integrate Prolaio's data and analytics platform into our product development, and her financial governance expertise will help guide our late-stage pipeline toward potential commercialization," Gianakakos said. Reinke joined Google when the company was considerably earlier in its development and has remained with its finance organization as the business expanded into a multibillion-dollar global enterprise. Before Google, she held leadership positions at Oracle and began her career at Arthur Andersen. Reinke also serves as an independent director of Everly Health, where she chairs the Audit Committee. She is a Certified Public Accountant and holds a bachelor's degree in accounting from Michigan State University. Her appointment comes alongside the departure of Giordano, whom Gianakakos credited for his role in the company's development as a founding board member. "We also would like to thank Doug, a founding member of our Board, for his profound impact over the last few years," Gianakakos said. Kardigan, which trades on Nasdaq under the ticker KARD, is a clinical-stage precision cardiovascular company developing therapies designed to address the underlying causes of cardiovascular diseases. The company is using patient data and analytics alongside its cardiovascular research capabilities to support more targeted drug development. With Reinke taking leadership of the Audit Committee, Kardigan is adding public-company financial oversight and large-scale technology experience to its board as it prepares its development programs for their next stages and builds the infrastructure required for potential commercialization.

Kardigan announces appointment of Kristin Reinke to its Board of Directors. SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., September 30, 2026-(BUSINESS WIRE)-Kardigan(TM), Inc. (Nasdaq: KARD) ("Kardigan"), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Board's public company evolution, Doug Giordano will be stepping down from the Board. Both Ms. Reinke's appointment and Mr. Giordano's departure are effective as of September 29, 2026. "Kristin's proven track record leading AI-driven transformation at global scale will be a great asset to help us achieve our mission of changing the future of cardiovascular care. Her experience turning technology into an operational advantage will be invaluable as we integrate Prolaio's data and analytics platform into our product development, and her financial governance expertise will help guide our late-stage pipeline toward potential commercialization. We're thrilled to welcome Kristin to the Kardigan Board and are fortunate to have her chair our Audit Committee," said Tassos Gianakakos, co-founder, chief executive officer, and chair of the board of Kardigan. "We also would like to thank Doug, a founding member of our Board, for his profound impact over the last few years." Ms. Reinke is currently vice president of finance at Google, where she leads the application of AI to modernize and scale the company's finance organization. A member of Google's finance leadership team since 2005, she has held roles spanning global FP&A, capital allocation, and controllership, helping the company grow from a startup into a multibillion-dollar global enterprise. She previously held leadership roles at Oracle and began her career at Arthur Andersen. Ms. Reinke serves on the board of Everly Health as an independent director and the audit committee chair. She is a CPA and holds a bachelor's degree in accounting from Michigan State University. About Kardigan Kardigan is a clinical-stage precision cardiovascular company developing medicines that target the root cause of diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies. Learn more about Kardigan and its mission at Kardigan.bio. Media: Michael Bachner Executive Director, Corporate Communications +1 (609) 664-7308 [email protected] Investors: Clayton Robertson Vice President, Investor Relations [email protected]

Kardigan makes strong Nasdaq debut following upsized IPO. Kardigan delivered a notable market debut on the Nasdaq, raising $400m in an upsized initial public offering. Shares of the cardiovascular treatment specialist opened at $16.25, above the $16 IPO price, before climbing more than 22% during the session. This performance underscores a resurgence in investor appetite for biotechnology firms boasting advanced clinical programs and robust growth prospects. Published on 06/18/2026 at 03:52 pm EDT Based in Princeton, New Jersey, Kardigan is developing several precision therapies for cardiovascular diseases. Its pipeline notably includes drug candidates danicamtiv, ataciguat, and tonlamarsen. Management has indicated that pivotal data regarding these three programs are expected during the first half of next year. The company was founded by Tassos Gianakakos and Jay Edelberg, two former executives who played key roles in the development of the heart medication mavacamten at MyoKardia, which was acquired by Bristol Myers Squibb for $13bn in 2020. This transaction takes place within a more favorable environment for biotech IPOs following several years defined by tighter access to capital. However, analysts point out that Kardigan may require additional financing in the medium term. The company stated in its regulatory filings that its current resources would not be sufficient to fund operations for at least twelve months without further capital injections, even though the funds raised are intended to accelerate the development of its clinical programs. (C) MarketScreener.com - 2026